Short Interest in NewAmsterdam Pharma (NASDAQ:NAMSW) Drops By 27.6%

NewAmsterdam Pharma (NASDAQ:NAMSW) saw a large drop in short interest in the month of September. As of September 15th, there was short interest totaling 2,100 shares, a drop of 27.6% from the August 31st total of 2,900 shares. Based on an average daily volume of 4,000 shares, the days-to-cover ratio is currently 0.5 days. Based on an average daily volume of 4,000 shares, the days-to-cover ratio is currently 0.5 days.

NewAmsterdam Pharma Stock Up 2.2%

Shares of NASDAQ NAMSW opened at $21.01 on Thursday. The stock’s fifty day simple moving average is $14.51 and its two-hundred day simple moving average is $10.93. NewAmsterdam Pharma has a 12-month low of $5.45 and a 12-month high of $22.00.

Institutional Trading of NewAmsterdam Pharma

A hedge fund recently raised its stake in NewAmsterdam Pharma stock. Affinity Asset Advisors LLC lifted its holdings in NewAmsterdam Pharma (NASDAQ:NAMSW) by 1.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 241,957 shares of the company’s stock after purchasing an additional 4,022 shares during the period. Affinity Asset Advisors LLC’s holdings in NewAmsterdam Pharma were worth $2,175,000 as of its most recent filing with the Securities & Exchange Commission.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.